Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

L Galicier1, N Schleinitz2

  • 1Service d'immunopathologie clinique, hôpital Saint-Louis, 75010 Paris, France.

La Revue De Medecine Interne
|January 19, 2023
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes of Kaposi sarcoma in people living with HIV who maintain long-term viral suppression: A prospective case-series.

HIV medicine·2026
Same author

[Health status and quality of life in β-thalassemia adults in Marseille, France].

La Revue de medecine interne·2024
Same author

[High anti-topoisomerase-1 autoantibodies levels are associated with the extension of skin fibrosis and vascular progression in patients with systemic sclerosis].

La Revue de medecine interne·2024
Same author

[IgG4-related disease: A proteiform pathology with frequent chest manifestations].

Revue des maladies respiratoires·2023
Same author

[Hospitalization for infection in patients treated for giant cell arteritis: A single-centre retrospective study].

La Revue de medecine interne·2023
Same author

[Why must we integrate carbon footprint in our prescriptions? The example of inhaler prescribing].

La Revue de medecine interne·2022

Castleman disease (CD) classification has improved, leading to better treatments for its diverse forms. Biotherapies targeting IL-6/6R and CD20 significantly enhance management for specific CD types.

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Castleman disease (CD) presents as a spectrum of disorders, with current classification identifying unicentric CD, multicentric HHV-8 associated CD, and idiopathic multicentric CD.
  • Idiopathic multicentric CD includes a severe variant, TAFRO syndrome (thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly).
  • Understanding CD pathophysiology has driven advancements in treatment strategies for both common and rare manifestations.

Approach:

  • This review synthesizes current knowledge on CD treatment strategies, drawing from relevant studies and expert consensus statements.
  • It examines therapeutic approaches for specific CD subtypes and associated severe conditions.
  • The review highlights the impact of novel biotherapies on disease management.

Key Points:

Keywords:
BiotherapyBiothérapieCastleman diseaseHuman Herpes Virus 8Interleukine-6Maladie de CastlemanTraitementTreatmentVirus herpès humain 8

Related Experiment Videos

  • Treatment for unicentric CD addresses manifestations like paraneoplastic pemphigus and bronchiolitis obliterans.
  • Management of HHV-8 associated CD includes addressing hemophagocytic syndrome and Kaposi's sarcoma.
  • Biotherapies targeting Interleukin-6 (IL-6)/IL-6 receptor (IL-6R) and CD20 have shown significant efficacy in certain CD forms.

Conclusions:

  • Improved classification and understanding of CD have led to more tailored and effective treatment strategies.
  • Biotherapies represent a major advancement in managing specific subtypes of Castleman disease.
  • Further research, including prospective studies, is needed to optimize treatment protocols for all CD forms.